Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149438 | 1.00 | NPC1 (0.71) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL29938562 | 1.00 | NPC1 (0.71) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL5620336 | 0.96 | NPC1 (0.68) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1299088 | 0.96 | MAPT (0.77) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14352146 | 0.91 | NPC1 (0.70) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1298504 | 0.91 | NPC1 (0.70) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL19367694 | 0.90 | MAPT (0.67) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL13572907 | 0.88 | TAAR1 (0.62) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL27907042 | 0.88 | ALDH1A1 (0.67) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL29708126 | 0.85 | MAPT (0.61) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-01 | — | — | US | disclosed |
| WO-2020249663-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| WO-2010015211-A1 | SYNTHESIS OF OXAZOLINE COMPOUNDS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | NME2, SLC28A1, SLC28A2 | NPC1 398/4885RAB9A 3010/4885MAPT 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.